Exudative Retinal Detachment

  • Haiying Zhou
  • Nan Zhou
  • Wenbin Wei


Systemic diseases and exudative retinal detachment include hypertensive retinopathy, retinopathy of nephropathy, and exudative retinal detachment related to eye diseases, such as Vogt-Koyanagi-Harada syndrome, central exudative chorioretinopathy, bullous retinal detachment, uveal effusion syndrome, posterior scleritis, sympathetic ophthalmia, acute posterior multifocal placoid pigment epitheliopathy, and exudative retinal detachment secondary to central retinal vein occlusion (CRVO).


  1. 1.
    Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the Management of Hypertension in the Community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32(1):3–15.CrossRefGoogle Scholar
  2. 2.
    Stropes LL, Luft FC. Hypertensive crisis with bilateral bullous retinal detachment. JAMA. 1977;238:1948–9.CrossRefGoogle Scholar
  3. 3.
    Sohan SH, Gray ES, Prem SV. Macular lesions in malignant arterial hypertension. Ophthalmologica. 1989;198(4):230–46.CrossRefGoogle Scholar
  4. 4.
    Report of the National High Blood Pressure Education Program. Working group report on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183:S1–S22.CrossRefGoogle Scholar
  5. 5.
    Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.CrossRefGoogle Scholar
  6. 6.
    Schachat AP, Markowitz JA, Guyer DR. Ophthalmic manifestations of leukemia. Arch Ophthalmol. 1989;107:697–700.CrossRefGoogle Scholar
  7. 7.
    Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease. Semin Ophthalmol. 2005;20:183–90.CrossRefGoogle Scholar
  8. 8.
    Rajendram R, Evans M, Rao NA. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2005;45(2):115–34.CrossRefGoogle Scholar
  9. 9.
    Chee SP, Jap A, Bacsal K. Spectrum of Vogt-Koyanagi-Harada disease in Singapore. Int Ophthalmol. 2007;27(2–3):137–42.CrossRefGoogle Scholar
  10. 10.
    Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114(3):606–14.CrossRefGoogle Scholar
  11. 11.
    Read RW, Rechodouni A, Butani N, Johnston R, LaBree LD, Smith RE, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;131(5):599–606.CrossRefGoogle Scholar
  12. 12.
    Naseripour M, Falavarjani KG, Sedaghat A, et al. Half-dose photodynamic therapy for chronic central serous chorioretinopathy. J Ophthalmic Vis Res. 2016;11(1):66–9.CrossRefGoogle Scholar
  13. 13.
    Liu HY, Yang CH, Yang CM, et al. Half-dose versus half-time photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol. 2016;167:57–64.CrossRefGoogle Scholar
  14. 14.
    Zhang C, Liu DN, Li XU. Intravitreal injection of lucentis for central exudative chorioretinopathy. Rec Adv Ophthalmol. 2014;34(9):864–7.Google Scholar
  15. 15.
    Gass GDM. Bullous retinal detachment: an unusual manifestation of idiopathic centre serous choroidopathy. Am J Ophthalmol. 1973;75:810–2.CrossRefGoogle Scholar
  16. 16.
    Mitsunaga H, Nishimura T, Yuyama M. Multifocal posterior pigment epitheliopathy: recently experienced cases. Jpn J Clin Ophthalmol. 1992;46:729–33.Google Scholar
  17. 17.
    Kuroyanagi K, Sakai T, Kasai K, Tsuneoka H. Spectral domain optical coherence tomography and angiographic findings in multifocal posterior pigment epitheliopathy treated with low-fluence photodynamic therapy. Clin Exp Optom. 2012;11(10):1111–4.Google Scholar
  18. 18.
    Ng WW, Wu ZH, Lai TY. Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report. J Med Case Rep. 2011;5:208.CrossRefGoogle Scholar
  19. 19.
    Schepens CL, Brockhurst RJ. Uveal effusion. 1. Clinical picture. Arch Ophthalmol. 1963;70:189–20.CrossRefGoogle Scholar
  20. 20.
    Uyama M, Takahashi K, Kozaki J, et al. Uveal effusion syndrome: clinical features, surgical treatment, histologic examination of the sclera, and pathophysiology. Ophthalmology. 2000;107:441–9.CrossRefGoogle Scholar
  21. 21.
    Forrester JV, Lee WR, Kerr PR, et al. The uveal effusion syndrome and trans-scleral flow. Eye (Lond). 1990;4:354–65.CrossRefGoogle Scholar
  22. 22.
    Liew SC, MeCluskey PJ, Parker G, et al. Bilateral uveal effusion associated with sclera thickening due to amyloidosis. Arch Ophthalmol. 2000;118(9):1293–5.CrossRefGoogle Scholar
  23. 23.
    Du Toit N, Motala MI, Richards J, et al. The risk of sympathetic ophthalmia following evisceration for penetrating eye injuries at Groote Schuur Hospital. Br J Ophthalmol. 2008;92:61–3.CrossRefGoogle Scholar
  24. 24.
    Makley TA Jr, Azar A. Sympathetic ophthalmia. A long-term follow-up. Arch Ophthalmol. 1978;96(2):257–62.CrossRefGoogle Scholar
  25. 25.
    Goto H, Rao NA. Sympathetic Ophthalmia and Vogt-Koyanagi-Harada syndrome. Int Ophthalmol Clin. 1990;30:279–85.CrossRefGoogle Scholar
  26. 26.
    Lubin JR, Albert DM, Weisntein M. Sixty-five years of sympathetic ophthalmia. A clinicopathologic review of 105 cases (1913–1978). Ophthalmology. 1980;87:109–12.CrossRefGoogle Scholar
  27. 27.
    Gass JDM. Acute pesterior multifocal placoid pigment epitheliopathy. Arch Ophthalmol. 1968;80:177–85.CrossRefGoogle Scholar
  28. 28.
    Gendy MG, Fawzi AA, Wendel RT, et al. Multimodal imaging in persistent placoid maculopathy. JAMA Ophthalmol. 2014;132(1):38–49.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and Beijing Science and Technology Press 2018

Authors and Affiliations

  • Haiying Zhou
    • 1
  • Nan Zhou
    • 1
  • Wenbin Wei
    • 1
  1. 1.Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical UniversityBeijingChina

Personalised recommendations